Switch theme
Sign up to access all valuation multiples
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.
2007
148
LTM Revenue $23.3M
LTM EBITDA -$56.4M
$236M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hansa Biopharma has a last 12-month revenue (LTM) of $23.3M and a last 12-month EBITDA of -$56.4M.
In the most recent fiscal year, Hansa Biopharma achieved revenue of $17.7M and an EBITDA of -$66.2M.
Hansa Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hansa Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $23.3M | XXX | $17.7M | XXX | XXX | XXX |
| Gross Profit | $16.0M | XXX | $9.1M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | -$56.4M | XXX | -$66.2M | XXX | XXX | XXX |
| EBITDA Margin | -242% | XXX | -375% | XXX | XXX | XXX |
| EBIT | -$57.4M | XXX | -$65.2M | XXX | XXX | XXX |
| EBIT Margin | -246% | XXX | -369% | XXX | XXX | XXX |
| Net Profit | -$67.4M | XXX | -$83.3M | XXX | XXX | XXX |
| Net Margin | -289% | XXX | -471% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $68.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hansa Biopharma's stock price is SEK 23 (or $2).
Hansa Biopharma has current market cap of SEK 1.5B (or $157M), and EV of SEK 2.3B (or $236M).
See Hansa Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $236M | $157M | XXX | XXX | XXX | XXX | $-1.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hansa Biopharma has market cap of $157M and EV of $236M.
Hansa Biopharma's trades at 13.4x EV/Revenue multiple, and -3.6x EV/EBITDA.
Equity research analysts estimate Hansa Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hansa Biopharma has a P/E ratio of -2.3x.
See valuation multiples for Hansa Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $157M | XXX | $157M | XXX | XXX | XXX |
| EV (current) | $236M | XXX | $236M | XXX | XXX | XXX |
| EV/Revenue | 10.1x | XXX | 13.4x | XXX | XXX | XXX |
| EV/EBITDA | -4.2x | XXX | -3.6x | XXX | XXX | XXX |
| EV/EBIT | -4.1x | XXX | -3.6x | XXX | XXX | XXX |
| EV/Gross Profit | 14.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.3x | XXX | -1.9x | XXX | XXX | XXX |
| EV/FCF | -3.8x | XXX | -3.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHansa Biopharma's last 12 month revenue growth is 78%
Hansa Biopharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.
Hansa Biopharma's rule of 40 is -448% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hansa Biopharma's rule of X is -47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hansa Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 78% | XXX | 78% | XXX | XXX | XXX |
| EBITDA Margin | -242% | XXX | -375% | XXX | XXX | XXX |
| EBITDA Growth | -20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -448% | XXX | -297% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -47% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 219% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 420% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hansa Biopharma acquired XXX companies to date.
Last acquisition by Hansa Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Hansa Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hansa Biopharma founded? | Hansa Biopharma was founded in 2007. |
| Where is Hansa Biopharma headquartered? | Hansa Biopharma is headquartered in Sweden. |
| How many employees does Hansa Biopharma have? | As of today, Hansa Biopharma has 148 employees. |
| Who is the CEO of Hansa Biopharma? | Hansa Biopharma's CEO is Mr. Soren Tulstrup. |
| Is Hansa Biopharma publicy listed? | Yes, Hansa Biopharma is a public company listed on STO. |
| What is the stock symbol of Hansa Biopharma? | Hansa Biopharma trades under HNSA ticker. |
| When did Hansa Biopharma go public? | Hansa Biopharma went public in 2007. |
| Who are competitors of Hansa Biopharma? | Similar companies to Hansa Biopharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hansa Biopharma? | Hansa Biopharma's current market cap is $157M |
| What is the current revenue of Hansa Biopharma? | Hansa Biopharma's last 12 months revenue is $23.3M. |
| What is the current revenue growth of Hansa Biopharma? | Hansa Biopharma revenue growth (NTM/LTM) is 78%. |
| What is the current EV/Revenue multiple of Hansa Biopharma? | Current revenue multiple of Hansa Biopharma is 10.1x. |
| Is Hansa Biopharma profitable? | Yes, Hansa Biopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hansa Biopharma? | Hansa Biopharma's last 12 months EBITDA is -$56.4M. |
| What is Hansa Biopharma's EBITDA margin? | Hansa Biopharma's last 12 months EBITDA margin is -242%. |
| What is the current EV/EBITDA multiple of Hansa Biopharma? | Current EBITDA multiple of Hansa Biopharma is -4.2x. |
| What is the current FCF of Hansa Biopharma? | Hansa Biopharma's last 12 months FCF is -$62.2M. |
| What is Hansa Biopharma's FCF margin? | Hansa Biopharma's last 12 months FCF margin is -267%. |
| What is the current EV/FCF multiple of Hansa Biopharma? | Current FCF multiple of Hansa Biopharma is -3.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
